Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics of isoniazid in low-birth-weight and premature infants.

Antimicrobial agents and chemotherapy - 1 Jan 2014

Bekker A, Schaaf H S, Seifart H I, Draper H R, Werely C J, Cotton M F, Hesseling A C

Abstract excerpt

Isoniazid (INH) is recommended for use as posttuberculosis exposure preventive therapy in children. However, no pharmacokinetic data are available for INH treatment in low-birth-weight (LBW) infants, who undergo substantial developmental and physiological changes. Our objectives in this study were to determine the pharmacokinetic parameters of INH at a dose of 10 mg/kg of body weight/day and to define its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Arylamine N-Acetyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to NAT2 gene

Share to Genotype

Share to Infant, Low Birth Weight

Share to Infant, Newborn

Share to Isoniazid

Share to Tuberculosis

Source

Open in PubMed Open full text

Identifiers

PMID: 24492365
DOI: 10.1128/AAC.01532-13
PMCID: PMC4023760

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics of isoniazid in low-birth-weight and premature infants.PMID 24492365Read ↗

Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.Semantic proximity Read ↗

Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.Semantic proximity Read ↗

Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.Semantic proximity Read ↗

The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.Semantic proximity Read ↗

Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy.Semantic proximity Read ↗

Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.Semantic proximity Read ↗

Pharmacokinetics of anti-tuberculosis drugs in children.Semantic proximity Read ↗

Parametric population pharmacokinetics of isoniazid: a systematic review.Semantic proximity Read ↗

Efficacy of isoniazid in paediatric tuberculosis: an individual participant data meta-analysis.Semantic proximity Read ↗

Model-Informed Precision Dosing of Isoniazid: Parametric Population Pharmacokinetics Model Repository.Semantic proximity Read ↗

Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.Semantic proximity Read ↗

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.